Overview
HUA MEDICINE-B (2552)
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing...
- Open
- 2.100
- High
- 2.100
- Low
- 2.015
- Prev. Close
- 2.175
- Volume
- 3.70M
- Turnover
- 7.65M
- Avg Price
- 2.068
- Bid/Ask Ratio
- 76.47%
- Amplitude
- 3.91%
- 52wk High
- 3.940
- Volume Ratio
- 1.34
- Turnover Ratio
- 0.35%
- 52wk Low
- 1.970
- HK Mkt Cap
- 2.19B
- Market CapHKD
- 2.19B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.117
- EPSDynamic
- -0.0658
- EPSStatic
- --
- BVPS
- 1.08
- P/B
- 1.91
- HK Shares
- 1.06B
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 1.06B
- Min lot size
- 500
- Currency
- HKD
HUA MEDICINE-B Analyst Rating
View moreForecast & Rating
Sep 16, 2026- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 2
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Jul, 3
Hua Medicine closed up 9.83% at HKD 2.57 today, driven by the expanded partnership with DKSH for the Hong Kong rollout of its diabetes drug Huatangning and a rebound from recent oversold levels. The stock opened 1.7% higher and surged to an intraday high of HKD 2.62 before paring gains, with a full-day range of 6.98%. Operationally, the company's Q4 2025 revenue surged 87.94% YoY to HKD 153.2 million, while net loss narrowed 24.83%, underscoring improving fundamentals. However, the stock remains 48.08% below its 52-week high of HKD 4.95 and below the 60-day moving average of HKD 2.994, suggesting the price recovery is still in its early stages.
- Jul, 2
华领医药今日低开高走,上午盘一度冲高至 2.440 港元后回落,下午盘重拾升势收于 2.370 港元,较前收 2.120 港元大涨 11.8%。主因是公司与大昌华嘉扩大合作支持香港糖尿病药物华堂宁上市的消息提振,叠加市场对近期香港获批上市及 ADA 2026 展示 Dorzagliatin 代谢疾病潜力的乐观情绪延续。基本面上,公司 Q4 2025 营收同比增长 87.94% 至 1.53 亿港元,净亏损同比收窄 24.83%,但净利率仍为-28.16%,显示商业化初期的盈利压力。目前股价较 52 周高点 4.95 港元折让 52.12%,同时站上 20 日均线 2.232 港元,反映短期动能改善但中期仍低于 60 日均线 3.012 港元,YTD 跌幅 22.3%。
News
Market Movers · Hua Medicine falls 4% in Hong Kong trading
Global Report · A USD 90 Million Upfront Anchors Hong Kong Biotech's December Rush
Global Report · Hong Kong's AI-pivot small caps run into the delivery test
Global Report · Biotech Reality Check: Profit Pioneers vs. Sector Misfits in Hong Kong's 2026 Healthcare Rally
Simplywall · 3 Stocks Retail Investors Are Watching In Oral GLP 1 Weight Loss Drugs
Global Report · The Signal for Hong Kong's Leftover Small Caps Comes From Abroad
